The trial was carried out by the German AGO Study Group and study centers in Bulgaria.
Aeterna’s AEZS-108 final Phase 2 results in endometrial cancers to be presented at ESGO 2011 Aeterna Zentaris Inc. The trial was carried out by the German AGO Study Group and study centers in Bulgaria. AEZS-108, a targeted cytotoxic peptide conjugate, is certainly in Phase 1/2 programs in prostate and bladder tumor currently, and has successfully completed Phase 2 trials in endometrial and ovarian cancer.The companies mentioned above that provide fake peer testimonials all come from countries and China in Southeast Asia, & most of the authors involved in these full cases result from the same areas. But it would be a mistake to look at this as a Chinese or Asian problem. The problem may be the perverse incentive systems in scientific publishing. Provided that authors are rewarded for publishing many articles and editors are rewarded for publishing them quickly, new means of gaming the traditional publication models will be invented quicker than new control steps can be put in place.
97 new medicines and vaccines in advancement for HIV/AIDS treatment, finds report Chemistry Globe recently highlighted a fresh survey published by the Pharmaceutical Analysis and Manufacturers of America that identifies 97 new medications and vaccines in advancement for HIV/AIDS and related conditions.